Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
8
×
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
8
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
gilead sciences
clinical trials
gene therapy
pfizer
amgen
astrazeneca
biogen
cancer
cancer immunotherapy
deals
glaxosmithkline
What
bio
roundup
drug
acquisitions
ceo
biggest
daniel
days
gilead
news
o’day
pharma
sciences
seven
today
abbvie’s
ahead
albert
american
announced
annual
approval
ash
august
away
biofourmis
biogen’s
biopharmaceutical
biotech
blood
borne
bourla
bringing
bucks
build
busy
buy
cancer
cancers
celebrate
Language
unset
unknown
Current search:
abbvie
×
" seattle top stories "
×
novartis
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More